CORT Corcept Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CORT

Price (delayed)

$24.74

Market cap

$2.63B

P/E Ratio

24.99

Dividend/share

N/A

EPS

$0.99

Enterprise value

$2.57B

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® ...

Highlights
The EPS has grown by 15% year-on-year and by 2.1% since the previous quarter
CORT's net income is up by 13% YoY
The quick ratio is down by 33% year-on-year but it is up by 23% since the previous quarter
The company's equity fell by 20% YoY but it rose by 9% QoQ
Corcept Therapeutics's debt has increased by 36% YoY
The P/E is 9% more than the 5-year quarterly average of 22.7 and 9% more than the last 4 quarters average of 22.7
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corcept.com
Peers: JNJ BMY LLY PFE

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
106.25M
Market cap
$2.63B
Enterprise value
$2.57B
Valuations
Price to earnings (P/E)
24.99
Price to book (P/B)
6.43
Price to sales (P/S)
6.9
EV/EBIT
19.52
EV/EBITDA
19.07
EV/Sales
6.76
Earnings
Revenue
$380.23M
EBIT
$131.61M
EBITDA
$134.73M
Free cash flow
$177.36M
Per share
EPS
$0.99
Free cash flow per share
$1.67
Book value per share
$3.85
Revenue per share
$3.59
TBVPS
$4.42
Balance sheet
Total assets
$468.12M
Total liabilities
$60.31M
Debt
$2.82M
Equity
$407.81M
Working capital
$330.98M
Liquidity
Debt to equity
0.01
Current ratio
6.78
Quick ratio
6.51
Net debt/EBITDA
-0.44
Margins
EBITDA margin
35.4%
Gross margin
98.6%
Net margin
29.4%
Operating margin
34.6%
Efficiency
Return on assets
21.9%
Return on equity
24.2%
Return on invested capital
34.5%
Return on capital employed
32%
Return on sales
34.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
1.48%
1 week
10.74%
1 month
17.81%
1 year
11.24%
YTD
24.95%
QTD
9.86%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$380.23M
Gross profit
$374.97M
Operating income
$131.61M
Net income
$111.84M
Gross margin
98.6%
Net margin
29.4%
Corcept Therapeutics's operating income has increased by 20% YoY and by 6% from the previous quarter
CORT's net income is up by 13% YoY
The gross profit is up by 12% year-on-year and by 4% since the previous quarter
The revenue rose by 12% year-on-year and by 3.9% since the previous quarter

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
P/E
24.99
P/B
6.43
P/S
6.9
EV/EBIT
19.52
EV/EBITDA
19.07
EV/Sales
6.76
The EPS has grown by 15% year-on-year and by 2.1% since the previous quarter
The P/E is 9% more than the 5-year quarterly average of 22.7 and 9% more than the last 4 quarters average of 22.7
The company's equity fell by 20% YoY but it rose by 9% QoQ
The stock's price to book (P/B) is 19% more than its last 4 quarters average of 5.3 but 13% less than its 5-year quarterly average of 7.3
The revenue rose by 12% year-on-year and by 3.9% since the previous quarter
CORT's P/S is 11% below its 5-year quarterly average of 7.6 but 3% above its last 4 quarters average of 6.6

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's ROIC is up by 39% year-on-year and by 13% since the previous quarter
The return on equity is up by 20% year-on-year and by 4.8% since the previous quarter
CORT's return on assets is up by 19% year-on-year and by 3.8% since the previous quarter
The return on sales has grown by 7% year-on-year

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The total liabilities has grown by 45% YoY and by 26% from the previous quarter
The company's current ratio fell by 33% YoY but it rose by 21% QoQ
Corcept Therapeutics's debt is 99% lower than its equity
Corcept Therapeutics's debt has increased by 36% YoY
The company's equity fell by 20% YoY but it rose by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.